Dantrolene (Dantrium, Dantrium Intravenous) shortage status
Widespread shortageTier 3: critical
Source: Health Canada shortage reports · Updated Oct 19, 2026
Dantrolene is in a widespread shortage in Canada. 2 of 4 reported products are affected, and Health Canada has designated this a Tier 3 (most serious) shortage. The latest manufacturer estimate for full recovery is Jan 31, 2027.
A muscle relaxant used to treat muscle spasticity and a rare reaction to anesthesia called malignant hyperthermia.
Products affected
2 / 4
In shortage since
Apr 20, 2026
Est. full return
Jan 31, 2027
Reports on file
13
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
DANTROLENE SODIUM FOR INJECTION, USP
20MG · POWDER FOR SOLUTION · HIKMA CANADA LIMITED
DIN 02529998 · since Aug 27, 2026, est. end Jan 31, 2027 · Demand increase for the drug.
Active shortage
DANTRIUM INTRAVENOUS
20MG · POWDER FOR SOLUTION · KNIGHT THERAPEUTICS INC.
DIN 01997572 · since Apr 20, 2026, no end estimate · Disruption of the manufacture of the drug.
Resolved
DANTROLENE SODIUM FOR INJECTION, USP
20MG · POWDER FOR SOLUTION · HIKMA CANADA LIMITED
DIN 02529998 · ended Jul 24, 2026 · Demand increase for the drug.
Resolved
DANTROLENE SODIUM FOR INJECTION, USP
20MG · POWDER FOR SOLUTION · HIKMA CANADA LIMITED
DIN 02529998 · ended Mar 26, 2026 · Disruption of the manufacture of the drug.
Resolved
DANTRIUM INTRAVENOUS
20MG · POWDER FOR SOLUTION · ENDO OPERATIONS LTD.
DIN 01997572 · ended Nov 7, 2025 · Demand increase for the drug.
Resolved
DANTROLENE SODIUM FOR INJECTION, USP
20MG · POWDER FOR SOLUTION · HIKMA CANADA LIMITED
DIN 02529998 · ended Sep 5, 2025 · Disruption of the manufacture of the drug.
Resolved
DANTROLENE SODIUM FOR INJECTION, USP
20MG · POWDER FOR SOLUTION · HIKMA CANADA LIMITED
DIN 02529998 · ended Aug 29, 2024 · Delay in shipping of the drug.
Resolved
DANTRIUM CAPSULES
25MG · CAPSULE · ENDO PAR INNOVATION COMPANY, LLC
DIN 01997602 · ended Feb 1, 2024 · Delay in shipping of the drug.
Resolved
DANTRIUM INTRAVENOUS
20MG · POWDER FOR SOLUTION · ENDO PAR INNOVATION COMPANY, LLC
DIN 01997572 · ended Jul 24, 2023 · Delay in shipping of the drug.
Resolved
DANTRIUM INTRAVENOUS
20MG · POWDER FOR SOLUTION · ENDO PAR INNOVATION COMPANY, LLC
DIN 01997572 · ended Dec 21, 2022 · Disruption of the manufacture of the drug.
Resolved
DANTRIUM INTRAVENOUS
20MG · POWDER FOR SOLUTION · PAR PHARMACEUTICAL COMPANIES
DIN 01997572 · ended Jul 30, 2018 · Demand increase for the drug.
Discontinued
DANTRIUM CAPSULES
100MG · CAPSULE · PAR PHARMACEUTICAL COMPANIES
DIN 01997653
Showing 12 of 13 reports. All reports are on file with Health Canada.
What's happening
Dantrolene is currently affected by 2 active shortage reports filed with Health Canada by HIKMA CANADA LIMITED, KNIGHT THERAPEUTICS INC..
The reported causes are: demand increase for the drug; disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
Health Canada has flagged this as a Tier 3 shortage, its most serious category, meaning the shortage has the greatest potential impact on the health system and alternatives are limited.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Dantrolene is classified under “MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS” (ATC M03CA).
Recent changes
Oct 19, 2026
Status changed
Oct 19, 2026
Estimated end date pushed back : Dec 18, 2026 → Jan 31, 2027
Oct 16, 2026
Tier 3 designation changed
Oct 16, 2026
Tier 3 designation changed
Aug 27, 2026
New report filed
Jul 27, 2026
Shortage resolved
Common questions
What is Dantrolene used for?
A muscle relaxant used to treat muscle spasticity and a rare reaction to anesthesia called malignant hyperthermia.
When will Dantrolene be back in stock in Canada?
The latest manufacturer estimate is Jan 31, 2027. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Dantrolene in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.